Concord Biotech Announces Q4 and FY2026 Financial Results, Recommends Dividend

Concord Biotech reported standalone profit after tax of ₹90.02 crore for Q4 FY2026, and consolidated PAT of ₹88.47 crore.

Reader Takeaway: Steady annual performance with a new subsidiary acquisition, offset by a one-time labour code expense.

What just happened

Concord Biotech Ltd. announced its audited standalone and consolidated financial results for the fourth quarter and the full fiscal year ending March 31, 2026. The company recommended a final dividend of ₹7.55 per equity share. Additionally, it completed the acquisition of Celliimune Biotech Private Limited as a wholly-owned subsidiary and appointed Mrs. Ekta Gupta as an Additional Independent Director.

Why this matters

The recommended dividend provides a direct return to shareholders. The acquisition of a new subsidiary signals strategic expansion. The unmodified auditor opinion offers assurance on financial reporting. An exceptional item related to employee benefits due to new Labour Codes was noted, which is a one-time impact.

The backstory

Concord Biotech is a biopharmaceutical company. This announcement covers its latest financial performance and corporate actions for the fiscal year 2026.

What changes now

Shareholders will be eligible for the recommended dividend, subject to approval at the AGM. The record date for this dividend is July 24, 2026. The company will now consolidate the financials of its new subsidiary, Celliimune Biotech Private Limited.

Risks to watch

The ₹3.28 crore exceptional item for employee benefit obligations due to new Labour Codes represents a one-time cost. Future implications of labour code implementations might need monitoring.

Peer comparison

(No direct peer comparison data available in the filing.)

Context metrics (time-bound)

• Standalone Revenue (Q4 FY26): ₹325.89 crore.
• Standalone PAT (Q4 FY26): ₹90.02 crore.
• Consolidated Revenue (Q4 FY26): ₹326.08 crore.
• Consolidated PAT (Q4 FY26): ₹88.47 crore.
• Exceptional Item (FY26): ₹3.28 crore towards employee benefit obligations.
• Dividend Recommended: ₹7.55 per equity share.
• Record Date: July 24, 2026.
• Subsidiary Acquisition: Celliimune Biotech Private Limited (completed April 2, 2026, with total consideration ₹0.66 crore).

What to track next

Investors should watch the performance of the newly acquired subsidiary and the company's ability to manage costs and integrate new operations. Monitoring the impact of labour code regulations on future expenses will also be crucial.